ABSTRACT

FLT3 internal tandem duplication mutations (FLT3 ITD
with AML and presence of such a mutation predicts for a worse outcome for patients, [1] [2] [3] particularly those with a high mutant to normal FLT3 allelic ratio. 4 An additional 5-7% of AML patients have an activating mutation of the FLT3 kinase activation loop.
5
There is substantial experimental and clinical evidence to support the hypothesis that FLT3 mutations are important in the initiation or maintenance of AML in some patients.
Activating mutations of FLT3 result in constitutive activation of FLT3 tyrosine kinase activity and can transform factor-dependent hematopoietic cells as evidenced by conversion to factorindependent growth and formation of tumors in immunodeficient mice. [6] [7] [8] In addition, retroviral transduction of primary murine bone marrow with a AML patient-derived FLT3-ITD cDNA results in a lethal myeloproliferative syndrome. 9 Finally, retroviral transduction of bone marrow derived from PML-RAR transgenic mice with FLT3-ITD results in a marked increase in the incidence of acute progranulocytic (APL)-like leukemia in such mice when compared to mice transplanted with mock transduced bone marrow. 10 For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From
These findings suggest that FLT3 may be a target for molecular therapy, analogous to that of BCR-ABL in chronic myeloid leukemia (CML). In CML, the use of single agent imatinib (STI571, Gleevec) is associated with impressive response rates and is now considered the standard front line non-transplant medical therapy. 11, 12 Agents capable of inhibiting FLT3 kinase have been developed and display promising pre-clinical activity. [13] [14] [15] [16] [17] [18] [19] These agents are capable of halting leukemic cell proliferation and inducing apoptosis in vitro and in different animal models. Several of these FLT3 inhibitors are currently being studied in phase I/II clinical trials of patients with AML but thus far have demonstrated only modest single agent activity. [20] [21] [22] These results are somewhat to analogous to those seen using imatinib to treat patients with CML was the experimental endpoint. SU11248 significantly inhibited the proliferation of FLT3 ITDpositive primary AML myeloblasts and the combination of SU11248 and cytarabine had a greater anti-proliferative effect than either agent used alone. In contrast, SU11248 had minimal activity against primary AML myeloblasts expressing WT FLT3 and the anti-proliferative effects of a combination of SU11248 and cytarabine were not significantly different than that seen using cytarabine as single agent. Our findings suggest that combining a FLT3 inhibitor such as SU11248 with standard anti-leukemia chemotherapy may improve clinical outcomes in AML. heterozygous for an ITD of DFREYE at amino acid position 593-598. 24 The cDNA for human FLT3 was cloned into the pLXSN retroviral vector. 25 Mutations encoding for a FLT3 ITD (reduplication of YEYDLK at amino acid positions 597-602) 16 and D835V were produced by site directed mutagenesis and confirmed by bi-directional sequencing. Retroviral packaging cells and/or cytarabine on the proliferation of primary AML myeloblasts was determined after 72-96 hours of treatment using an XTT-based assay. In the experiments involving a combination of SU11248 and cytarabine, the two agents were added simultaneously to the cells. 27 In the experiments involving a combination of SU11248 and cytarabine or daunorubicin, the two agents were added simultaneously to the cells.
MATERIALS AND METHODS
Cell
Immunoblotting
Data Analysis.
Results from experiments were analyzed using the median effect method of Chou and Talalay (Calcusyn Software available from Biosoft, Cambridge, UK). 28 Individual agents were tested to determine the dose required to inhibit proliferation of cells to 50% of untreated controls (ED 50 ). Doses of 4 times, 2 times, 1 times, 0.5 times, and 0.25 times the ED 50 were then analyzed using the Calcusyn software program to create isobolograms and calculate
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From combination indices (CI). The combination index was calculated using the more stringent statistical assumption of mutually non-exclusive modes of action. Specifically: 
RESULTS
Effects of Combinations of Cytarabine and SU11248 on Cellular Proliferation
We have previously reported that SU11248 inhibits FLT3 kinase activity in AML cell lines and selectively inhibits proliferation and induces apoptosis in cell lines with a FLT3-ITD mutation. 17 Cytarabine is one of the most active chemotherapeutic agents for the treatment of AML and it remains the backbone of induction and consolidation regimens. 23, 29 To determine if inhibition of FLT3 kinase in AML cells might potentiate the effects of cytarabine, we performed experiments in which fixed doses of SU11248 were added to increasing doses of cytarabine to test if a combination of the agents would prove more effective than either agent used alone.
MV4-11 cells, known to be hemizygous for a FLT3 ITD mutation, 16 For a more quantitative analysis of the apparent synergistic interaction between cytarabine and SU11248, we performed fixed ratio dilution experiments. The results from these experiments were used to create isobolograms and calculate combination indices (CI) for various levels of drug activity. Three separate cell lines with known juxtamembrane tandem duplications in FLT3 were employed in our combination studies: MOLM14 cells (heterozygous for an ITD mutation), a BAF3 cell line engineered to express human FLT3 with an ITD mutation (BAF3 ITD FLT3), and MV4-11 cells (hemizygous for an ITD mutation). The different mutations of these cell lines provide a spectrum of ITD mutations and also reduce potential bias from idiosyncrasies of any individual cell line. In addition, we performed similar experiments using factor-independent BAF3 D835V FLT3, and FL-dependent BAF3 WT FLT3.
Experiments were performed with each cell line to determine the concentrations of cytarabine or SU11248 capable of decreasing proliferation to 50% of untreated control cells (ED 50 ). As noted previously, the ED 50 for SU11248 inhibition of proliferation was significantly lower for cells expressing FLT3 ITD as compared with FL-activated WT FLT3 or D835V.
Specifically, the ED 50 for inhibition of MV4-11, MOLM14, and BAF3 ITD FLT3 were 8 nM, 12
nM, and 8 nM, respectively (X-intercept values in Figure 2 ). In contrast, the ED 50 values for SU11248 inhibition of the proliferation of FL-activated WT FLT3 and factor-independent FLT3 D835V expressing cells were 50 and 110 nM, respectively.
Cells were treated with cytarabine, SU11248, or both agents at 4 times, 2 times, 1 times, ½ times, and ¼ times the ED 50 . Analysis of the data using the method of Chou and Talalay 
Figure 2. Isobolograms and CI values for the effects of SU11248 and cytarabine on cellular proliferation
Cells were incubated with cytarabine, SU11248, or both for 72 hours and proliferation was assessed using an XTT based assay. Results were analyzed using Calcusyn software for (A) MV4-11 (B) MOLM14, (C) BAF3 ITD FLT3, (D) FL-stimulated BAF3 WT FLT3, and (E) BAF3 D835V FLT3 cell lines (concentrations of agents are expressed in nM). For 90% inhibition (ED 90 ), the points fall to the left of the predicted line of additive effect, suggesting a synergistic interaction of cytarabine and SU11248. The drugs appear to have an additive effect for doses necessary to inhibit proliferation at 50% of untreated control. The simulated isobolograms define a "dose of equivalence" for the agents. Experimental results that fall near the line suggest that combinations of the two agents have an additive effect.
Experimental results falling to the left of the line indicate better than additive effects of combining the agents (i.e. synergy). Experimental results that fall far to the right of the line indicate that the two agents have antagonistic effects. In our experiments the observed effect for the concentration of the two agents necessary to inhibit cells by 90% (ED 90 ) fell to the left of the line of dose equivalence for all five tested cell lines. Adding SU11248 at low nM doses markedly reduced the amount of cytarabine necessary to achieve any given amount of antiproliferative effect. CI values for the observed effects on proliferation were also computed. For the experiments with the five cell lines, the ED 90 CI was less than 1, suggesting a better than additive effect of combining SU11248 and cytarabine.
SU11248 is a multi-targeted kinase inhibitor, with potent activity against KIT, PDGFRA, PDGFRB, FLT3, CSF-1R, and VEGFR2. 17, 30 To confirm that the observed antiproliferative effects were solely due to the activity of SU11248 against FLT3 and not one or more other SU11248 target kinases, we compared the effects of SU11248, SU6668, and SU14816 (imatinib) on the proliferation of the different cell lines. SU6668 inhibits KIT, PDGFRA, PDGFRB and VEGFR2 but not FLT3, 31, 32 whereas SU14816 inhibits KIT, PDGFRA, PDGFRB but not FLT3, CSF-1R, or VEGFR2. 27, 33 All five cell lines were inhibited by SU11248 but not by other potent inhibitors targeting KIT, PDGFRA, PDGFRB or VEGFR2 (SU14816 at 1000 nM, SU6668 at 500-3000 nM, data not shown). The effect of SU11248 on the proliferation of BAF3 derived cell lines expressing mutant or WT FLT3 was completely abrogated when IL-3 was provided as alternative growth factor. In addition, SU11248 in doses up to 3000 nM had no effect on the Based on these results, we conclude that anti-proliferative effects of SU11248 on the factorindependent growth of the mutant FLT3 cell lines and the FL-dependent growth of WT FLT3 BAF3 cell line used in our experiments are mediated entirely by inhibition of FLT3 kinase.
Effects of Combinations of Daunorubicin and SU11248 on Cellular Proliferation
Anthracyclines are another class of chemotherapeutic agents commonly used in the treatment of AML. 23 Therefore, we performed experiments to determine the efficacy of the combination of SU11248 and daunorubicin. The ED 50 for daunorubicin was determined separately for each cell line. Cells were then treated with daunorubicin, SU11248, or both agents at 4 times, 2 times, 1 times, ½ times, and ¼ times the ED 50 .
For For personal use only. on September 14, 2017. by guest www.bloodjournal.org From All five of the cell lines were sensitive to daunorubicin in a 10-80 nM dose range. In the isobolograms (figure 3), the actual experimental points lie very near the lines of equivalence for the MV4-11 and MOLM14 cell lines, indicating that the combination of daunorubicin and SU11248 has an additive rather than synergistic effect on the proliferation of MV4-11 and MOLM-14 lines. This is also reflected in the calculated CI values that are approximately equal to 1. In contrast, the experimental values for the combination of SU11248 and daunorubicin fall significantly to the left of the lines of equivalence for all three BAF3 derived cell lines, indicating that the combination has a synergistic effect. This is also reflected in the calculated CI values that are significantly less than 1.
Effects of Combinations of Cytarabine and SU11248 on Induction of Apoptosis
Our XTT-based "proliferation" assays directly measure the number of metabolically viable cells for each treatment condition. Thus, both cytostatic and cytotoxic effects of the single agents and combinations are reflected in the assay results. Previous studies have demonstrated that potent FLT3 inhibitors are capable of selectively inducing apoptosis in cell lines containing FLT3 ITD mutations. 13, 15, 19, 34 Since the combination of SU11248 with traditional cytotoxic agents increased the "anti-proliferative" effects of chemotherapy, we sought to determine whether the combination of SU11248 with anti-leukemia chemotherapy drugs actually increased cell killing when compared to single agent therapy. MV4-11 cells were treated with single agent SU11248 (25 nM or 50 nM) or single agent cytarabine at (2 µM or 4 µM). Additionally cells were treated with combinations of these agents: 25 nM SU11248 with either 2 µM or 4µM
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From cytarabine. Apoptosis was assessed at 24 hours using immunoblotting for proteolytic cleavage of poly (ADP-ribose) polymerase (PARP) (Figure 4) . Cytarabine and SU11248 were both capable of inducing apoptosis in a dose dependent manner, as assessed by PARP cleavage. However the combination of the lowest doses of both agents (2 µM cytarabine and 25 nM SU11248) produced a greater effect than those seen using twice the dose of either agent alone suggesting a synergistic interaction. The small amount of full length PARP detectable after treatment with either agent alone was absent when the agents were combined.
In order to more precisely evaluate synergy using a mathematical model, we utilized a more quantitative assessment of apoptosis in our subsequent experiments. Analysis of apoptosis with flow cytometry using Annexin V-FITC and propidium iodide provides a convenient method to quantify apoptotic and/or non-viable cell populations. For these experiments we used MV4- 
Effects of Combinations of Daunorubicin and SU11248 on Induction of Apoptosis
Similar to the apoptosis experiments with cytarabine, cells were treated with daunorubicin and SU11248 either as individual agents or in combination and then analyzed using 
In Vitro Effects of SU11248 and Cytarabine on Primary Human AML Cells
To further test whether our cell line model observations might be relevant to the treatment of human AML, we isolated low density peripheral blood mononuclear cells from five patients with refractory and/or multiply relapsed AML. The FLT3 ITD status of the five patients was determined by D-HPLC and DNA sequencing, 3 patients had unique FLT3 ITDs (REYEYDL595-601 after L601, FREYEYDLKWEFPRENL594-610 after N609, YEYDLKWEFPRENLEF597-612 after F612, respectively) and 2 patients had no mutation of the FLT3 juxtamembrane or activation loop domains. For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From durable remissions and are rarely cured. In addition, the elderly are usually not candidates for more intensive therapy using autologous or allogeneic stem cell transplantation. Although advances in supportive care have improved treatment-related mortality, the overall cure rate in adult AML has not improved significantly in the last decade. This plateau has lead to a search for newer therapies that might target fundamental molecular abnormalities in AML cells. [36] [37] [38] [39] The recent success of imatinib mesylate (Gleevec, Glivec, formerly STI571), in treating CML has fueled enthusiasm for the further development of targeted therapies for AML. 11, 12 Logically, such therapies should be most efficacious if the target is a critical molecular mechanism initiating or maintaining the leukemic state. Although the weight of evidence suggests that translocations involving transcriptional machinery are the initiating event in many cases of AML, in most instances it is not yet possible to effectively target these abnormalities. 40 The lone exception has been the development of all trans-retinoic acid (ATRA) therapy for the treatment of APL. 41 New approaches to selective inhibition of specific histone deacetylases and disruption of pathological transcription factor complexes are urgently needed. In contrast, substantial progress has been made in the development of specific tyrosine kinase inhibitors.
To date, FLT3 mutations are one of the most attractive AML targets yet identified, as these mutations are one of the most common molecular abnormalities found in cases of AML.
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A number of potent and selective FLT3 tyrosine kinase inhibitors have been developed and characterized in pre-clinical models. [13] [14] [15] [16] [17] [18] 35 Several of these FLT3 inhibitors are being testing in ongoing phase I/II trials for patients with refractory AML. [20] [21] [22] [23] mutations appear to be a later event that increases the proliferation of a pre-existing neoplastic clone. 40, 48 The most successful application of molecularly targeted therapy in AML to date has been the use of ATRA in the treatment of APL. Treatment of APL with ATRA as a single agent results in early remission but unacceptably high relapse rates. However, the use of ATRA in combination with traditional chemotherapeutic agents produces the highest sustained remissions rate of any FAB sub-type of AML. 41, 49 This example suggests that the most effective use of targeted agents in AML may be in combination with standard AML chemotherapy agents.
In our experiments we have shown the feasibility of combining a FLT3 inhibitor, SU11248, with standard AML chemotherapy drugs. SU11248 increased the anti-proliferative effects of cytarabine and daunorubicin on FLT3 ITD containing cell lines. Low concentrations of this agent reduced the dose of cytotoxic agent necessary to produce any given antiproliferative effect. More importantly, adding SU11248 to cytotoxic agents resulted in strong synergistic effects for the induction of apoptosis of the leukemic cell lines. The ability of SU11248 to induce apoptosis in leukemia cells when added to traditional chemotherapy drugs demonstrates that these combinations are potently cytotoxic rather then merely cytostatic.
We attempted to validate the potential clinical relevance of these observations using cultured primary AML myeloblasts. In these experiments, SU11248 significantly inhibited the proliferation of FLT3 ITD-positive AML myeloblasts and the combination of SU11248 and cytarabine had a greater anti-proliferative effect than either agent used alone. In contrast, SU11248 had minimal activity against primary AML myeloblasts expressing WT FLT3 and the anti-proliferative effects of a combination of SU11248 and cytarabine were not significantly different than that seen using cytarabine as single agent. The major side effects of standard AML chemotherapy are mucositis, cardiac toxicity prolonged myelosuppression, bleeding, and infection. 23 Extensive testing of single agent FLT3
inhibitors in animals and limited testing in humans does not indicate that these agents cause mucositis or cardiac toxicity. In animal models, myelosuppression does not appear to be a significant side effect of FLT3 inhibitors. Grade 3 or 4 myelosuppression in solid tumor patients being treated with SU11248 was uncommon; fatigue and hypertension were the dose limiting toxicities of this agent. [50] [51] [52] [53] The effects of SU11248 on the blood counts ofAML patients may be more difficult to interpret as myelosuppression may result from suppression of the leukemic clone rather than an effect on normal hematopoietic cells. However, it seems feasible that a combination of standard AML chemotherapy agents and a FLT3 inhibitor such as SU11248 could result in increased clinical efficacy without necessarily increasing the toxicity of either agent. Based on our results, further clinical development of such an approach seems warranted.
In addition to the possible use of full dose chemotherapy regimens in combination with 
